Cargando…

The impact of age on a mitoxantrone-based tumor vaccine

Detalles Bibliográficos
Autores principales:	Stonewall, Keven, Quintero, Cecilia, Zloza, Andrew, Kaufman, Howard, Ruby, Carl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991350/ http://dx.doi.org/10.1186/2051-1426-1-S1-P234

Ejemplares similares

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment
por: Broucek, Joseph, et al.
Publicado: (2014)

Acute viral infection results in a PD-1-dependent loss of anti-tumor CD8+ T cell responses: implications for tumor immunotherapy
por: Kohlhapp, Frederick, et al.
Publicado: (2015)

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex
por: Zloza, Andrew, et al.
Publicado: (2013)

Single-step nanoparticle antigen presentation system for tumor immunotherapy
por: Kohlhapp, Frederick, et al.
Publicado: (2015)

PD-1 blockade reverses viral infection-induced loss of anti-tumor CD8+ T cell responses
por: Huelsmann, Erica, et al.
Publicado: (2013)

Seasonal and age-related variations impacting HPV vaccination uptake in Romania
por: Streinu-Cercel, Oana, et al.
Publicado: (2013)

A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone
por: Resta, Lee P., et al.
Publicado: (2010)

Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells
por: Kim, Dae Won, et al.
Publicado: (2014)

Developing Community Advisory Board guidelines for AIDS vaccine trials in China
por: Kaufman, JA, et al.
Publicado: (2012)

P11-03. Mucosal trafficking and differentiation of vaccine-elicited CD8+ T-lymphocytes
por: Kaufman, DR, et al.
Publicado: (2009)

Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model
por: Shafren, Darren, et al.
Publicado: (2014)

Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines
por: Dillman, Robert O, et al.
Publicado: (2015)

Inhibition of tumor growth in vivo by a nanoparticle-based therapeutic cancer vaccine targeting HAAH
por: Fuller, Steven, et al.
Publicado: (2013)

Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease
por: Hughes, Tasha, et al.
Publicado: (2013)

The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)
por: Hughes, Tasha, et al.
Publicado: (2013)

Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer
por: Chesson, Charles B, et al.
Publicado: (2017)

Erratum: Oncolytic viruses: a new class of immunotherapy drugs
por: Kaufman, Howard L., et al.
Publicado: (2016)

Oncolytic viruses: a new class of immunotherapy drugs
por: Kaufman, Howard L., et al.
Publicado: (2015)

Design, development and production of nano-particle-based anticancer vaccine targeting human aspartyl (asparaginyl) β-hydroxylase (HAAH)
por: Biswas, Biswajit, et al.
Publicado: (2013)

Impact of Anthocyanidins on Mitoxantrone-Induced Cytotoxicity and Genotoxicity: An In Vitro and In Vivo Analysis
por: Dhivya, Sridaran, et al.
Publicado: (2016)

Defining the effects of age and gender on clinical immune response to cancer vaccination
por: Ramirez, Adriana, et al.
Publicado: (2014)

Tumor vascular normalization as a strategy to potentiate effectiveness of therapeutic vaccines
por: Farsaci, Benedetto, et al.
Publicado: (2014)

Mitoxantrone and Mitoxantrone-Loaded Iron Oxide Nanoparticles Induce Cell Death in Human Pancreatic Ductal Adenocarcinoma Cell Spheroids
por: Dinter, Jonas, et al.
Publicado: (2023)

Polysaccharide-based nanoparticles for co-loading mitoxantrone and verapamil to overcome multidrug resistance in breast tumor
por: Xu, Yurui, et al.
Publicado: (2017)

P-147: COVID-19, impact of vaccination in myeloma patients
por: Hoornaert, Ellen, et al.
Publicado: (2021)

Vaccination with pre-diagnostic tumor antigens but not established tumor antigens inhibits spontaneous tumorigenesis in TgMMTV-neu mice
por: Stanton, Sasha E, et al.
Publicado: (2013)

Vaccine-induced tumor regression requires a multi-step cooperation between T cells and myeloid cells at the tumor site
por: Thoreau, Maxime, et al.
Publicado: (2015)

Fractionated but not single dose radiation releases key signals of in situ tumor vaccination
por: Vanpouille-Box, Claire, et al.
Publicado: (2014)

The use of malignant serosal fluid as a tumor vaccine in patients with advance malignancies
por: Katakkar, Suresh
Publicado: (2015)

Mitoxantrone-Surfactant Interactions: A Physicochemical Overview
por: Enache, Mirela, et al.
Publicado: (2016)

Late Cardiotoxicity in MS Patients Treated with Mitoxantrone
por: Najafian, Jamshid, et al.
Publicado: (2019)

P15-26. Leveraging motivators to participation in HIV vaccine research in the age of Obama
por: Alexander, SB, et al.
Publicado: (2009)

Effects of tyrosine kinase inhibitors alone or in combination with vaccine on tumor-infiltrating myeloid cells
por: Donahue, Renee N, et al.
Publicado: (2013)

Colony stimulating factors secreted by irradiated autologous tumor cell vaccines inhibit immunity
por: Ravindranathan, Sruthi, et al.
Publicado: (2015)

The impact of metabolic stress on anti-tumor immunity in laboratory mice
por: Kokolus, Kathleen M, et al.
Publicado: (2013)

The impact of β-adrenergic signaling on radioresistance and anti-tumor immunity
por: Bucsek, Mark, et al.
Publicado: (2015)

Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response
por: Antonios, Joseph, et al.
Publicado: (2015)

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014)

Epitope-based vaccines: SARS – a model
por: Freund, Natalia Tarnovitski, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_0n7p8is0b8ul782m5smbgdc4ej